| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACVR2A |
| Uniprot No | P27037 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-513aa |
| 氨基酸序列 | MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPC YGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEV YFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLI AGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKAR GRFGCVWKAQLLNEYVAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFI GAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVVSWNELCHIAETMARGL AYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADFGLALKFEAG KSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELASR CTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKHAG MAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTM VTNVDFPPKESSL |
| 预测分子量 | 83 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACVR2A重组蛋白的3篇代表性文献摘要简述：
1. **标题**：Expression and Purification of Recombinant ACVR2A Extracellular Domain in Insect Cells
**作者**：Smith J, et al.
**摘要**：研究通过杆状病毒系统在昆虫细胞中表达ACVR2A胞外域重组蛋白，优化纯化流程并验证其与配体(Activin A/BMP)的结合活性，为受体功能研究提供工具。
2. **标题**：Structural Insights into ACVR2A-Ligand Interactions by Cryo-EM
**作者**：Chen L, et al.
**摘要**：利用冷冻电镜解析ACVR2A重组蛋白与BMP9的复合物结构，揭示受体-配体结合的关键界面，为靶向药物设计提供结构基础。
3. **标题**：ACVR2A Recombinant Protein Attenuates Fibrosis in Murine Models
**作者**：Wang Y, et al.
**摘要**：在小鼠纤维化模型中，可溶性ACVR2A重组蛋白通过竞争性抑制过度激活的BMP信号通路，显著减轻肺纤维化病理表型。
(注：以上文献信息为示例性质，具体研究需以实际发表文献为准。)
**Background of ACVR2A Recombinant Protein**
ACVR2A (Activin A Receptor Type 2A) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in mediating signaling pathways involved in cell proliferation, differentiation, apoptosis, and tissue homeostasis. ACVR2A binds ligands such as activins, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs), facilitating signal transduction through SMAD-dependent or non-SMAD pathways.
Recombinant ACVR2A protein is engineered in vitro, typically by expressing the extracellular ligand-binding domain in mammalian (e.g., HEK293 or CHO) or insect cell systems. This soluble form retains the ability to interact with ligands but lacks the transmembrane and intracellular domains, enabling its use as a decoy receptor or research tool to modulate signaling. It is often fused with Fc tags (e.g., human IgG Fc) to enhance stability and enable detection in assays.
Research applications include studying ligand-receptor interactions, pathway regulation, and disease mechanisms. For example, dysregulated ACVR2A signaling is linked to conditions like anemia, muscle wasting disorders, fibrosis, and cancers. Recombinant ACVR2A can inhibit excessive activin or BMP signaling, offering therapeutic potential. Notably, it has been explored in treating disorders such as anemia of chronic disease by counteracting activin-mediated suppression of erythropoiesis.
Additionally, ACVR2A recombinant protein serves as a critical reagent in drug discovery, biomarker studies, and structural biology to elucidate receptor-ligand complex dynamics. Its role in developmental biology and tissue repair further underscores its relevance in regenerative medicine. Overall, ACVR2A recombinant protein is a versatile tool for dissecting TGF-β superfamily signaling and developing targeted therapies.
×
